Oslo, August 7, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI) today announced that it has received notice from deputy board member…
Data demonstrate that extracellular ASC specks, independent of IL-1β, govern the pathogenesis and extent of amyloid A (AA) amyloidosis, which…
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development…
CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a…
Company’s academic co-founder from the Wellcome Sanger Institute will lead Quotient’s Somatic Genomics researchCAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE)…
SOL-R AXPAXLI™ Repeat Dosing Study in Wet AMD Acceptable to FDA as Registrational Trial Enrollment in SOL-1 Continues to Accelerate…
Rachael Buck Ph. D, Velocity UK Country Head Rachael Buck Ph. D, Velocity UK Country Head DURHAM, N.C., Aug. 07,…
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…
MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies…
August 7, 2024News Release BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting COPENHAGEN, DENMARK and BOSTON, MA,…